A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of Anti-IL17A Therapy for Venous Leg Ulcers
July 2023
in “
Journal of the European Academy of Dermatology and Venereology
”
Studysummary In a Phase II trial, Cox and colleagues reported that anti-IL17A therapy was well tolerated and led to a 64% reduction in wound size for venous leg ulcers unresponsive to standard treatments, although further validation in a larger trial is needed.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on onlinelibrary.wiley.com →